Information Library

Results for: Central Laboratories - Europe

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Partnering is Key to Maximizing Rewards in Emerging Markets

    Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.

  • Digital Pathology Central Laboratory Services Fact Sheet

    Brochure — June 23, 2011
    This fact sheet highlights Quintiles' digital pathology services, covering everything from scanning of slides to review and analysis - giving you a faster, easier way to scan and share this critical research data.

  • Genomics Fact Sheet

    Brochure — June 17, 2011
    Approximately 20% of today’s U.S. Clinical Trials use genomic technology. Find out about Quintiles’ offerings in this area.

  • Quintiles and Population Genetics Technologies Partner

    Press Release — May 16, 2011 – Quintiles, and Population Genetics Technologies Ltd. (PGT), announced a commercial collaboration to bring genomic testing into mainstream drug development in order to produce safer, more effective medicines.

  • Dr. Frank Massam

    Hear from the Experts — May 13, 2011
    Dr. Frank Massam discusses the significance of Quintiles' partnership with Population Genetics Technologies Ltd.

  • Biomarkers in Alzheimers Disease

    Presentation — March 17, 2011
    The Quintiles Innovation Unit shares their knowledge on the use of biomarkers in compound development in clinical trials.

  • Scientific Bulletin Flow Cytometry

    Case Study — February 9, 2011
    Quintiles has expertise in running highly regulated flow cytometry assays, as well as a number of esoteric assays, such as multicolor cell surface and intracellular staining assays, and receptor occupancy/competitive binding assays.

  • Bypassing Barriers - Refractory Partial Epilepsy

    Case Study — February 2, 2011
    Despite a difficult and limited patient population, Quintiles randomized 388 patients (13 over target) 10 weeks ahead of schedule.

  • Diabetes - Therapeutic Focus

    Case Study — February 1, 2011
    A dose-ranging clinical study to evaluate the safety, efficacy and tolerability of five doses of Drug X compared with placebo in Type II diabetes patients with no prior exposure to anti-diabetic medication.

  • Acute Coronary Syndrome - Tailored Solutions

    Case Study — February 1, 2011
    Find out how our experience in multi-national cardiovascular clinical trials helped this customer reach database lock 66 days after LPO.

Page 1 of 2 (14 results)

Subscribe to Email Based on Your Interests

Set preferences